Rgenta Therapeutics
Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.
Founded
2018Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.
Rgenta Therapeutics, founded with the mission to develop RNA-targeting medicines, focuses on creating oral, small-molecule treatments for oncology and neurological disorders. Utilizing a proprietary platform, Rgenta mines genomics data to identify targetable RNA processing events and designs small-molecule glues to modulate interactions among the spliceosome, regulatory proteins, and RNAs. This innovative approach aims to unlock the therapeutic potential of historically undruggable targets in human diseases.
Notable affiliated individuals include experts in genomics and drug development, contributing to the company's cutting-edge research. Rgenta has successfully raised $52 million in Series A financing, underscoring investor confidence in its potential. The company's pioneering work in RNA-targeting medicines has the potential to significantly impact the treatment landscape for previously incurable diseases, positioning Rgenta as a leader in the biopharmaceutical industry.
Companies similar to Rgenta Therapeutics include ReNAgade Therapeutics, ReviR Therapeutics, Tacit Therapeutics and Remix Therapeutics.
Rgenta Therapeutics was founded in 2018.
Rgenta Therapeutics' headquarters is located in Woburn, MA, US.
Rgenta Therapeutics' most recent funding round was for $8M (USD) in May 2023.
As of May 8, 2023, Rgenta Therapeutics has disclosed funding of $116.9M (USD). Undisclosed round amounts are excluded.
Rgenta Therapeutics has 35 employees as of Feb 5, 2024.
Remix Therapeutics
remixtx.com
